Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NBIO thin thin thin
The door is wide freaking open for a run to $1
$NBIO Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
Nascent Biotech Inc. (OTCQB: NBIO)
Nascent Biotech is a development stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioma and astrocytoma. Pritumumab is a monoclonal antibody that has been tested in Ministry of Health and Welfare approved clinical studies in 249 human brain cancer patients in the nation of Japan. The objective of the Phase I and Phase II human clinical trial was to determine the safety of pritumumab in humans and its efficacy in eliminating tumors or reducing tumor size in patients with brain cancer.
Recent News
https://finance.yahoo.com/news/nascent-biotech-announces-fast-eligibility-123000444.html
https://finance.yahoo.com/news/nascent-biotech-announces-completion-1-171700110.html
$NBIO Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
April 4, 2018/in Corporate News /
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
Click this link to download a PDF detailing the conference details, and how to register.
Nascent Biotech Inc. (OTCQB: NBIO)
Nascent Biotech is a development stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioma and astrocytoma. Pritumumab is a monoclonal antibody that has been tested in Ministry of Health and Welfare approved clinical studies in 249 human brain cancer patients in the nation of Japan. The objective of the Phase I and Phase II human clinical trial was to determine the safety of pritumumab in humans and its efficacy in eliminating tumors or reducing tumor size in patients with brain cancer.
Share Structure
Market Cap
13,785,699
06/07/2018
Authorized Shares
100,000,000
05/31/2018
Outstanding Shares
28,134,079
05/31/2018
Restricted
19,723,969
05/31/2018
Unrestricted
8,410,110
05/31/2018
Held at DTC
3,247,470
05/31/2018
Float
5,056,710
08/07/2017
Par Value
0.00
Recent News
https://finance.yahoo.com/news/nascent-biotech-announces-fast-eligibility-123000444.html
https://finance.yahoo.com/news/nascent-biotech-announces-completion-1-171700110.html
$NBIO Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
April 4, 2018/in Corporate News /
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
Click this link to download a PDF detailing the conference details, and how to register.
Nascent Biotech Inc. (OTCQB: NBIO)
Nascent Biotech is a development stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioma and astrocytoma. Pritumumab is a monoclonal antibody that has been tested in Ministry of Health and Welfare approved clinical studies in 249 human brain cancer patients in the nation of Japan. The objective of the Phase I and Phase II human clinical trial was to determine the safety of pritumumab in humans and its efficacy in eliminating tumors or reducing tumor size in patients with brain cancer.
Share Structure
Market Cap
13,785,699
06/07/2018
Authorized Shares
100,000,000
05/31/2018
Outstanding Shares
28,134,079
05/31/2018
Restricted
19,723,969
05/31/2018
Unrestricted
8,410,110
05/31/2018
Held at DTC
3,247,470
05/31/2018
Float
5,056,710
08/07/2017
Par Value
0.00
Recent News
https://finance.yahoo.com/news/nascent-biotech-announces-fast-eligibility-123000444.html
https://finance.yahoo.com/news/nascent-biotech-announces-completion-1-171700110.html
Active OTCQB 2018. Clinical trials being conducted as I type. Get ready for fireworks.
$NBIO
OTCQB 2018
No Toxic Debt
2 drugs in clinical trials
Multi year volume highs
It’s waking up!!!
This is one you don’t want to miss.
$NBIO
QB 2018
No Toxic Debt
2 drugs in clinical trials
Multi year volume highs
It’s waking up!!!
This is one you don’t want to miss.
$NBIO....We have a banger here.
$NBIO get some!
28,000,000 od
.31 $NBIO
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
April 4, 2018/in Corporate News /
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
$NBIO
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
April 4, 2018/in Corporate News /
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
April 4, 2018/in Corporate News /
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
$NBIO COME ON FELLAS, YOU ALL KNOW BETTER. DITCH THE PIGS. LETS WALK ON AIR
MPID ASK PRICE SIZE TIME
CANT 0.31 13,500 12:42
CSTI 0.65 1,000 11:30
VNDM 0.75 1,000 12:40
CDEL 1.44 120 12:46
NITE 1.50 2,150 12:41
MAXM 200.00 1 07:35
ETRF U 0 13:06
LOVE IT WHEN ITS PAPER THIN? LOVE IT WHEN ITS READY TO POP?
$NBIO $NBIO
28,000,000 OS
PAPER THIN
AMAZING DRUG IN TRIALS
52 WEEK HIGH
ITS ON WAKE UP FOLKS, DITCH YOU FAT PIGS AND WALK ON AIR.
https://www.otcmarkets.com/stock/NBIO/overview
LOVE IT WHEN ITS PAPER THIN? LOVE IT WHEN ITS READY TO POP?
$NBIO $NBIO
28,000,000 OS
PAPER THIN
AMAZING DRUG IN TRIALS
52 WEEK HIGH
ITS ON WAKE UP FOLKS, DITCH YOU FAT PIGS AND WALK ON AIR.
Yo SP you want to make some coin, look at $NBIO
Things brewing and this is razor thin....
$NBIO Lets get it!
28,000,000 OS
$5.00 Coming!!!!!
$NBIO
$NBIO Lets get it!
28,000,000 OS
$5.00 Coming!!!!!
$NBIO Lets get it!
28,000,000 OS
$5.00 Coming!!!!!
$NBIO
Unusual volume
52 week high
28,000,000 OS
$5.00 Coming!!!!!
$NBIO screaming from the top of the mountain here.
Unusual volume
52 week high
28,000,000 OS
$5.00 Coming!!!!!
$NBIO screaming from the top of the mountain here.
Unusual volume
52 week high
28,000,000 OS
$5.00 Coming!!!!!
$NBIO pounding the freaking table here fellas.
$NBIO is the next play 100%, time to load hold and thank me later. Its on!!!
Something is brewing here.
$NBIO, its about to get weird fellas.
UNUSUAL VOLUME LAST WEEK.
Load up now and thank me later. Badabing!!!!!!!!!!!!!!
UNUSUAL VOLUME LAST WEEK.
$NBIO, its about to get weird fellas.
UNUSUAL VOLUME LAST WEEK.
$NBIO, its about to get weird fellas.
$NBIO is straight up about to go parabolic. Super thin. No volume for years. People are silently loading. Get your tickets fellas.
$NBIO Unusual volume this morning. Woke from the dead. Biotech at .20. Moves on air. Could be something brewing.
$NBIO biotech unusual volume. At .20 moves on air.
$NBIO biotech unusual volume. At .20 moves on air.
$NBIO unusually volume at .20. Moves on air. Something cooking IMO.
NBIO unusual volume alert! Moves on air.
Under $6,000,000 in annual revenue for a lab in the addiction treatment market with access to the capital markets is an absolute freaking joke.
SCAMMERS taking advantage of the sheep.
Bankruptcy and indictments is the only future here.
Garbage heap
This is an absolute dumpster fire. The yearly revenue is an absolute joke given they own labs. Labs are a freaking cash machine. You can generate that revenue in a few months of one substantial tox account. This is a joke of a company. Too many employees too much stock too many business ventures, All failures.
By reverse splits.
No bid by close of business. Nothing has changed here fellas, and it hasn't for years. This is not even an operating company. This is a shell that has been dark for years.
Yes sir just a stock selling scam company here IMO.
Buyer Beware... Do your research. The history is there.